See the DrugPatentWatch profile for Rexulti
Rexulti 2023 Sales in the U.S.
In 2023, Rexulti generated $1.2 billion in net sales in the U.S. [1]. This figure represents a significant increase from previous years, driven by its use in treating major depressive disorder (MDD) and schizophrenia [2].
How has Rexulti's sales performance changed over time?
Rexulti's sales in the U.S. have seen consistent growth. In 2022, U.S. net sales for the drug were $963 million [3]. The 2023 figures show a substantial jump, reflecting its expanding market penetration and therapeutic applications [2].
What conditions is Rexulti approved to treat?
Rexulti is approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy, and for schizophrenia in adults and pediatric patients aged 13 and older [2][4]. Its efficacy in these indications contributes to its sales performance.
What is the mechanism of action for Rexulti?
Rexulti is a dopamine-D2 partial agonist and a serotonin-2A (5-HT2A) partial agonist [4]. This dual action is believed to modulate dopaminergic and serotonergic neurotransmission, which plays a role in mood and psychosis regulation [4].
When does Rexulti's patent protection expire?
Patent information for Rexulti is complex and subject to ongoing legal developments. DrugPatentWatch.com tracks patent expiry dates and exclusivities for pharmaceuticals. Information regarding Rexulti's specific patent landscape can be found on their platform [1].
Who are Rexulti's main competitors in the U.S. market?
In the treatment of MDD, Rexulti competes with other adjunctive therapies and standalone antidepressants. For schizophrenia, its competitors include a range of antipsychotic medications. The competitive landscape is dynamic, with new treatments and generics emerging [2].
What are the reported side effects of Rexulti?
Common side effects associated with Rexulti include weight gain, somnolence, and akathisia [4]. Patients and healthcare providers consider these factors when choosing treatment options.
What clinical data supports Rexulti's efficacy?
Clinical trials have demonstrated Rexulti's effectiveness in reducing depressive symptoms when used as an add-on therapy for MDD, and in improving positive and negative symptoms of schizophrenia [2][4].
What is the typical dosage and administration of Rexulti?
Rexulti is available in oral tablet form and is typically taken once daily. Dosage is individualized based on the patient's condition and response [4].
Are there any alternative treatments for depression and schizophrenia?
Alternative treatments for MDD include various antidepressant medications, psychotherapy, and other adjunctive therapies. For schizophrenia, a range of antipsychotic medications are available, as well as psychosocial interventions [2].
What is the pricing of Rexulti in the U.S.?
Pricing for Rexulti can vary depending on insurance coverage, pharmacy, and patient assistance programs. Information on drug pricing is typically available through pharmaceutical manufacturers and healthcare cost transparency tools [2].
What is the regulatory status of Rexulti in the U.S.?
Rexulti is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses [4]. The FDA monitors post-market safety and efficacy data for all approved medications.
---
Sources:
[1] DrugPatentWatch.com (Information regarding Rexulti's patent landscape can be found on their platform.)
[2] Company financial reports and press releases (Specific details on sales and market performance.)
[3] Otsuka Pharmaceutical Co., Ltd. and Lundbeck A/S financial disclosures (Data for 2022 sales.)
[4] Rexulti Prescribing Information (Official FDA-approved labeling for the drug.)